Stock EWL EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Edwards Lifesciences Corporation Deutsche Boerse AG

Equities

EWL

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Deutsche Boerse AG
Other stock markets
 07:20:01 08/05/2024 BST 		After market 21:00:01
79.54 EUR +1.83% Intraday chart for Edwards Lifesciences Corporation 79.19 -0.44%
05-07 Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100 MT
05-01 Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48,657 56,859 80,883 46,128 46,246 51,727 - -
Enterprise Value (EV) 1 48,073 56,271 80,616 45,956 45,198 50,047 48,888 46,895
P/E ratio 47.3 x 70.2 x 54.4 x 30.6 x 33.2 x 32 x 27.7 x 25.6 x
Yield - - - - - - - -
Capitalization / Revenue 11.2 x 13 x 15.5 x 8.57 x 7.7 x 7.89 x 7.18 x 6.56 x
EV / Revenue 11.1 x 12.8 x 15.4 x 8.54 x 7.53 x 7.63 x 6.79 x 5.95 x
EV / EBITDA 34.2 x 39.4 x 46.6 x 23.7 x 24.1 x 24.3 x 21.1 x 18.2 x
EV / FCF 52 x 86.9 x 57.3 x 47.2 x 47.9 x 34.3 x 30.3 x 26.7 x
FCF Yield 1.92% 1.15% 1.74% 2.12% 2.09% 2.91% 3.31% 3.75%
Price to Book 12 x 12.7 x 13.9 x 7.82 x 6.99 x 6.49 x 5.3 x 4.34 x
Nbr of stocks (in thousands) 625,710 623,248 624,334 618,260 606,500 602,600 - -
Reference price 2 77.76 91.23 129.6 74.61 76.25 85.09 85.09 85.09
Announcement Date 30/01/20 27/01/21 26/01/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,348 4,386 5,232 5,382 6,005 6,560 7,201 7,880
EBITDA 1 1,406 1,429 1,729 1,936 1,879 2,062 2,321 2,578
EBIT 1 1,316 1,322 1,594 1,796 1,734 1,903 2,162 2,415
Operating Margin 30.28% 30.14% 30.47% 33.38% 28.87% 29.02% 30.02% 30.64%
Earnings before Tax (EBT) 1 1,166 916.7 1,702 1,767 1,598 1,906 2,234 2,490
Net income 1 1,047 823.4 1,503 1,522 1,402 1,622 1,864 2,022
Net margin 24.08% 18.77% 28.73% 28.28% 23.35% 24.73% 25.89% 25.66%
EPS 2 1.643 1.300 2.380 2.440 2.300 2.659 3.077 3.324
Free Cash Flow 1 925 647.3 1,406 973.6 943 1,458 1,616 1,759
FCF margin 21.27% 14.76% 26.88% 18.09% 15.7% 22.22% 22.44% 22.32%
FCF Conversion (EBITDA) 65.8% 45.29% 81.32% 50.29% 50.19% 70.68% 69.62% 68.22%
FCF Conversion (Net income) 88.36% 78.61% 93.56% 63.97% 67.24% 89.85% 86.67% 87%
Dividend per Share 2 - - - - - - - -
Announcement Date 30/01/20 27/01/21 26/01/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,330 1,341 1,374 1,319 1,348 1,460 1,530 1,481 1,534 1,598 1,656 1,622 1,685 1,741 1,809
EBITDA 1 398 479.4 480 492.8 483.9 469.3 485.6 458.7 465.1 477.6 522.6 514.6 542.3 557.6 585.8
EBIT 1 365 444.7 445.9 457.4 448.5 434.1 449.5 421.8 428.4 439.1 480.3 475.1 503.3 515.2 545.3
Operating Margin 27.45% 33.16% 32.46% 34.68% 33.26% 29.74% 29.38% 28.48% 27.93% 27.47% 29.01% 29.29% 29.87% 29.59% 30.14%
Earnings before Tax (EBT) 1 376.3 436.1 464.7 407.3 459.3 398.6 338.5 439.3 421.7 409.4 489.9 484.2 508.6 525 557.5
Net income 1 335.3 373.6 406.4 343.5 398.4 340.5 307.1 384.9 369.9 351.9 411.5 406.3 428.8 434.7 465.5
Net margin 25.22% 27.86% 29.58% 26.04% 29.55% 23.33% 20.07% 25.99% 24.11% 22.02% 24.85% 25.04% 25.45% 24.97% 25.74%
EPS 2 0.5300 0.5900 0.6500 0.5500 0.6500 0.5600 0.5000 0.6300 0.6100 0.5800 0.6801 0.6708 0.7135 0.7242 0.7750
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 26/01/22 26/04/22 28/07/22 27/10/22 31/01/23 26/04/23 26/07/23 25/10/23 06/02/24 25/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 585 588 267 173 1,048 1,680 2,839 4,832
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 925 647 1,406 974 943 1,458 1,616 1,759
ROE (net income / shareholders' equity) 32.5% 26.9% 27% 26.6% 22.5% 22.6% 21.8% 19.8%
ROA (Net income/ Total Assets) 20% 17.1% 17.8% 18.5% 15.9% 16.7% 16.7% 15.5%
Assets 1 5,227 4,814 8,426 8,242 8,828 9,726 11,167 13,018
Book Value Per Share 2 6.500 7.190 9.350 9.550 10.90 13.10 16.00 19.60
Cash Flow per Share 2 1.850 1.670 2.740 1.950 1.470 3.020 3.240 3.490
Capex 1 254 407 326 245 253 289 296 331
Capex / Sales 5.85% 9.28% 6.23% 4.54% 4.21% 4.4% 4.11% 4.2%
Announcement Date 30/01/20 27/01/21 26/01/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Edwards Lifesciences Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
85.84 USD
Average target price
95.27 USD
Spread / Average Target
+10.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+7.87% 184B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+12.75% 138B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-1.37% 62.54B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.88% 52.22B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+2.71% 41.4B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+4.90% 37.17B
RESMED, INC. Stock ResMed, Inc.
+23.75% 31.76B
PHILIPS NV Stock Philips NV
+15.48% 24.18B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. EW Stock
  4. EWL Stock
  5. Financials Edwards Lifesciences Corporation